Capital Fund Management S.A. Crispr Therapeutics Ag Transaction History
Capital Fund Management S.A.
- $37.9 Billion
- Q4 2024
A detailed history of Capital Fund Management S.A. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Capital Fund Management S.A. holds 18,097 shares of CRSP stock, worth $615,840. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,097
Previous 50,104
63.88%
Holding current value
$615,840
Previous $2.35 Million
69.75%
% of portfolio
0.0%
Previous 0.01%
Shares
18 transactions
Others Institutions Holding CRSP
# of Institutions
485Shares Held
64.1MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$305 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$298 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$130 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$94.5 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.75MShares$93.4 Million0.07% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $2.65B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....